BACKGROUND: Agonist binding at the benzodiazepine site of γ-aminobutric acid type A receptors diminishes anxiety and insomnia by actions in the amygdala. The neurochemical effects of benzodiazepine site agonists remain incompletely understood. Cholinergic neurotransmission modulates amygdala function, and this study tested the hypothesis that benzodiazepine site agonists alter acetylcholine (ACh) release in the amygdala. METHODS: Microdialysis and high-performance liquid chromatography quantified ACh release in the amygdala of Sprague-Dawley rats (n = 33). ACh was measured before and after IV administration (3 mg/kg) of midazolam or eszopiclone, with and without anesthesia. ACh in isoflurane-anesthetized rats during dialysis with Ringer's solution (control) was compared with ACh release during dialysis with Ringer's solution containing (100 μM) midazolam, diazepam, eszopiclone, or zolpidem. RESULTS: In unanesthetized rats, ACh in the amygdala was decreased by IV midazolam (−51.1%; P = 0.0029; 95% confidence interval [CI], −73.0% to −29.2%) and eszopiclone (−39.6%; P = 0.0222; 95% CI, −69.8% to −9.3%). In anesthetized rats, ACh in the amygdala was decreased by IV administration of midazolam (−46.2%; P = 0.0041; 95% CI, −67.9% to −24.5%) and eszopiclone (−34.0%; P = 0.0009; 95% CI, −44.7% to −23.3%), and increased by amygdala delivery of diazepam (43.2%; P = 0.0434; 95% CI, 2.1% to 84.3%) and eszopiclone (222.2%; P = 0.0159; 95% CI, 68.5% to 375.8%). CONCLUSIONS: ACh release in the amygdala was decreased by IV delivery of midazolam and eszopiclone. Dialysis delivery directly into the amygdala caused either increased (eszopiclone and diazepam) or likely no significant change (midazolam and zolpidem) in ACh release. These contrasting effects of delivery route on ACh release support the interpretation that systemically administered midazolam and eszopiclone decrease ACh release in the amygdala by acting on neuronal systems outside the amygdala. (Anesth Analg 2014;118:1293-300) www.anesthesia-analgesia.org aNesthesia & aNalgesia Quantifying ACh Levels in the Amygdala High-performance liquid chromatography with electrochemical detection (Bioanalytical Systems, West Lafayette, IN) was used to measure ACh release (pmol/12.5 minutes) in the amygdala. Chromatograms were digitized and quantified using Chromgraph Software (Bioanalytical Systems, West Lafayette, IN) in reference to a 7-point standard curve ranging from 0.05 to1.0 pmol of ACh. CMA/11 microdialysis probes (CMA Microdialysis, Stockholm, Sweden) had a cuprophane membrane of 1 mm in length and 0.24 mm in diameter, and a molecular cutoff of 6000 Da. The probes were perfused continuously with Ringer's solution (147 mM NaCl, 2.4 mM CaCl 2 , 4.0 mM KCl, 10 μM neostigmine, and pH 6.0 ± 0.2). Perfusion flow rate was held constant at 2.0 μL/min by a CMA/400 syringe pump (CMA Microdialysis, Stockholm, Sweden). Before and after every experiment, the percent recovery of ACh by each dialysis probe was quantified in vitro to ensure that measured changes in ACh were not an artifact of intra-experimental changes in probe membrane function. As described previously, [17] [18] [19] [20] [21] the physical characteristics of the CMA/11 probe membranes are such that they delivered approximately 5% of the drug concentration used to perfuse the probes. Thus, for the present study that used a drug concentration of 100 μM, it can be estimated that the concentration of drug delivered by dialysis to the amygdala was about 5 μM.
Experimental Design
All sedative/hypnotics used in this study are BZ site agonists. Midazolam and diazepam are benzodiazepines. Eszopiclone and zolpidem are cyclopyrrolones (i.e., nonbenzodiazepines) that bind to the BZ site on γ-aminobutric acid type A (GABA A ) receptors. Three experimental approaches were used ( Fig. 1 ). First, ACh release was measured in the amygdala of unanesthetized rats before and after IV administration of BZ site agonists (Fig. 1A) . Second, ACh release was quantified after IV administration of BZ site agonists to rats that were anesthetized with isoflurane ( Fig. 1B) . Third, ACh release was measured while reverse dialysis was used to deliver BZ site agonists into the amygdala of isoflurane-anesthetized rats (Fig. 1C ).
Study 1. Quantifying ACh Release in the Amygdala of Unanesthetized Rats Before and After IV Administration of BZ Site Agonists
At least 1 week before the experiment, rats (n = 9) were anesthetized with isoflurane, and the percent of delivered isoflurane was monitored continuously by spectrometry (Cardiocap TM/5 , Datex-Ohmeda, Louisville, CO). A rectal thermistor (GE Healthcare, Finland) was placed to measure core body temperature, which was maintained between 36ºC and 38ºC. A chronic jugular-vein catheter (Micro-Renathane tubing, MRE-040, Braintree Scientific, MA) was implanted to provide a route for systemic drug administration. An injection port (8I313000BM10, Plastics One, Roanoke, VA) was attached to the exterior end of the catheter between the Green boxes indicate when dialysis samples containing acetylcholine (ACh) (the dependent measure) were obtained. A, Rats were implanted with a chronic jugular-vein cannula and a microdialysis guide cannula. Intact, unanesthetized rats were used to measure ACh release in the amygdala before and after administration of benzodiazepine (BZ) site agonists via the previously implanted jugular-vein cannula. B, Measurements of ACh release in the amygdala (Amyg) from isoflurane-anesthetized rats were obtained while drugs were delivered via an acute, jugular-vein catheter (JVC). C, Microdialysis delivery of BZ site agonists directly to the amygdala during isoflurane anesthesia. scapulae ( Fig. 1A ) and sealed with a cap (8IC313DCCACC, Plastics One). After placement of the catheter, the rat was positioned in a Kopf Model 962 stereotaxic frame (David Kopf Instruments, Tujunga, CA) with a Kopf model 920 rat adaptor and rat anesthesia mask (Kopf model 906). A craniotomy was performed, and a CMA/11 guide cannula was implanted at 2.3 mm posterior to bregma, 4.0 mm lateral to midline, and 3.5 mm above the amygdala (CeA), according to a rat brain atlas. 22 Three stainless steel anchor screws (MPX-00800-02-C, Small Parts Inc., Miami Lakes, FL) were inserted into the skull. The guide cannula was fixed to the skull with dental acrylic (Lang's Jet Acrylic, Lang Dental Mfg. Co., Wheeling, WV).
During the recovery period, rats were handled daily and conditioned to being placed in a Plexiglas recording chamber (Raturn, Bioanalytical Systems, West Lafayette, IN). Rats had free access to food and water. On the day of the experiment, a microdialysis probe was inserted into the CeA guide cannula. The probe was perfused continuously with Ringer's solution (2 μL/min). A syringe containing either midazolam or eszopiclone was connected to the jugular-vein catheter with a 55 cm length of Micro-Renathane tubing. This tubing made it possible to perform drug injections without handling the animals. Rats were kept awake during collection of the first 5 dialysis samples (12.5 minutes/sample) before drug administration. This procedure ensured all rats were in the same state of consciousness before systemic drug delivery, and these samples provided control levels of ACh. Next, saline, midazolam (3 mg/kg), or eszopiclone (3 mg/kg) was administered IV at a rate of 200 μL/min, and 5 additional dialysis samples were collected. At the end of every experiment, the microdialysis probe was removed, the connector for the jugular-vein catheter connector was disconnected, and the animal was returned to its home cage.
Study 2. Quantifying ACh Release in the Amygdala of Isoflurane-Anesthetized Rats Before and after IV Administration of BZ Site Agonists
Rats (n = 6) were anesthetized with 4% isoflurane in 100% oxygen. Delivered isoflurane concentration then was reduced to 2.5%. A catheter (Micro-Renathane tubing, MRE-040) was inserted into 1 jugular vein ( Fig. 1B) . After placement of the catheter, the rat was positioned in a stereotaxic frame. A craniotomy was performed, and a CMA/11 microdialysis probe was aimed for the CeA (2.3 mm posterior to bregma, 4.0 mm lateral to midline, and 8.5 mm below the skull surface) according to a rat brain atlas. 22 After stereotaxic positioning of the microdialysis probe, delivered isoflurane concentration was decreased to 1.5% and maintained at this level for the remainder of the experiment.
The microdialysis probe was perfused continuously with Ringer's solution (2 μL/min) during the course of sample collection. Five microdialysis samples (each 25 μL) were collected from the amygdala before and after IV administration (200 μL/min) of midazolam (3 mg/kg) and eszopiclone (3 mg/kg). After collection of the last dialysis sample, the jugular-vein catheter and the microdialysis probe were removed, and all incisions were closed. Isoflurane delivery was discontinued, and the animal recovered before being returned to its home cage.
Study 3. Quantifying ACh Release in the Amygdala During Microdialysis Delivery of BZ Site Agonists to the Amygdala of Isoflurane-Anesthetized Rats
Each rat (n = 18) was anesthetized, placed in a stereotaxic frame, and a microdialysis probe was aimed for the amygdala as described above (Fig. 2B ). Five microdialysis samples were collected during dialysis with Ringer's solution (control). A CMA/110 liquid switch was then activated to perfuse the probe with Ringer's solution alone, or Ringer's solution containing midazolam (100 μM, Hospira, Lake Forest, IL), diazepam (100 μM, Sigma-Aldrich, St. Louis, MO), eszopiclone (100 μM, Toronto Research Chemicals, Toronto, Canada), zolpidem (100 μM, Sigma-Aldrich, St. Louis, MO), or tetrodotoxin (TTX, 1 μM). Five microdialysis samples were obtained during dialysis administration of BZ site agonists. This within-subjects design was used to test only 1 drug per rat (Fig. 2C ). After collection of the last sample, the dialysis probe was removed from the brain, the scalp was closed, and delivery of isoflurane was discontinued.
Histological Confirmation of Dialysis Sites
Three to 7 days after each experiment, rats were deeply anesthetized and decapitated. Brains were removed, frozen, and sectioned coronally at a thickness of 40 μm. Serial sections were slide-mounted, dried, fixed with paraformaldehyde vapor at 80ºC, and stained with cresyl violet. Tissue sections were compared with a rat brain atlas 22 to localize microdialysis sites.
Statistical Analyses
In consultation with a statistician at the University of Michigan Center for Statistical Consultation and Research, data were analyzed with Statistical Analysis System v9.3, (SAS Institute, Inc., Cary, NC) software. First, each animal's ACh values were calculated as percent change from the mean of the animal's control values. These values appeared to be relatively symmetrically distributed and required no further transformation. Second, a linear mixed model was fitted in which the percentage ACh release was the dependent variable, and treatment (control versus drug) was used as the independent variable. A random effect (i.e., random intercept) was also included for each animal to consider the fact that each animal provided multiple, possibly correlated ACh samples for each treatment. A P value <0.05 was considered statistically significant. Residuals were assessed for normality. Figures 3-5 are shown as mean percent change + SD. Results of statistical tests comparing the effects on ACh release of each drug to its control are reported with mean percentage difference, P value, and 95% confidence interval (CI). These CIs consider the correlation among observations on the same animal.
RESULTS
For each animal, measures of ACh were included in the analyses only if histological results (Fig. 2) confirmed that those measures were obtained from the amygdaloid nuclear complex. Figure 2A shows coronal brain sections that were modified from an atlas 22 Figure 2C schematically illustrates the anterior-to-posterior span of the dialysis sites in the amygdaloid nuclear complex. A representative cresyl violet-stained section used to confirm microdialysis probe placement within the amygdaloid nuclear complex is shown in Figure 2D .
Drug-induced changes in neurotransmitter levels can result from alterations in neurotransmitter synthesis, degradation, or release. Dialysis delivery of the sodium channel blocker TTX is a standard technique for inferring action potential-dependent release of a measured transmitter. 23, 24 Before quantifying the effects of the BZ site agonists, the amygdala of rats (n = 3) was dialyzed with Ringer's solution containing TTX (1 μM). The results (no figure presented) revealed that compared with ACh measured during microdialysis with Ringer's solution (control), TTX caused a significant decrease of −39.7% (P = 0.0158, 95% CI, −67.0% to −12.3%) in ACh release. The finding that TTX caused an approximately 40% decrease in ACh release in rat amygdala can be compared with TTX causing a 55% decrease in ACh release measured in mouse prefrontal cortex, 23 and TTX causing a 58% decrease in ACh release within the pontine reticular formation of mice. 24 The TTXinduced decrease of ACh in rats supports the interpretation that a portion of the present microdialysis measures reflects action potential-dependent ACh release in the amygdala.
Additional control experiments were essential for confirming that ACh release changed as a function of administered BZ site agonists. Therefore, 2 additional control studies were performed to ensure that ACh release measured from the amygdala was stable throughout the 125-minute interval required to collect microdialysis samples. One study followed the design shown in Fig. 1C . The results (not illustrated) revealed that compared with ACh release measured during the first 62.5-minute dialysis with Ringer's solution, there was no significant difference in ACh release during the subsequent 62.5-minute dialysis with Ringer's solution (mean difference = 8.3%; P = 0.5509; 95% CI, −27.1% to 43.7%; n = 3 rats). A similar series of control experiments, performed according to the design illustrated by Fig. 1A , revealed that IV administration of saline to unanesthetized rats caused a nonsignificant change −16.4% (P = 0.1192; 95% CI, −39.4% to 6.6%) in ACh release (n = 3 animals, data not shown). These control experiments verified that measures of ACh were stable and free of procedural confounds. The foregoing control experiments provided a basis for the results summarized by Figs. 3, 4 , and 5.
Study 1 (n = 3 animals per drug) was designed to quantify ACh release in the amygdala before and after BZ site agonists were administered systemically to intact, unanesthetized Control experiments - A Figure 2 . Histologic confirmation of dialysis sites. A, The coronal plates were modified from a rat brain atlas 22 to illustrate the location of microdialysis sites within the amygdala. The size of the dialysis membrane is indicated by the cylinders drawn to scale, relative to the brain. rats. The results demonstrate that IV administration of midazolam (Fig. 3A ) caused a significant (P = 0.0029; 95% CI, −73.0% to −29.2%) decrease of −51.1% in ACh release. Likewise, ACh release in the amygdala was significantly (P = 0.0222; 95% CI, −69.8% to −9.3%) decreased (−39.6%) by eszopiclone (Fig. 3B ).
The results from study 2 (n = 3 animals per drug) show ACh release in the amygdala of isoflurane-anesthetized rats before (Ringer's solution) and after IV administration of midazolam (Fig. 4A) or eszopiclone (Fig. 4B) . ACh release was significantly (P = 0.0041; 95% CI, −67.9% to (Fig. 5A) into the amygdala of isoflurane-anesthetized rats nonsignificantly (P = 0.0814; 95% CI, −2.6% to 29.0%) changed ACh release within the amygdala by 13.2%. Figure 5B shows that dialysis delivery of diazepam to the amygdala caused a significant (P = 0.0434; 95% CI, 2.0% to 84.3%) increase of 43.2% in ACh release. Figure 5C illustrates that microdialysis delivery of eszopiclone to the amygdala also significantly (P = 0.0159; 95% CI, 68.5% to 375.8%) increased ACh release in the amygdala by 222.2%. There was no significant (P = 0.2674; 95% CI, −18.6% to 50.9%) difference (16.1%) in ACh release comparing zolpidem with control ( Fig. 5D ).
DISCUSSION
The anxiolytic and sedating properties of the BZ site agonists used in this study are well documented. The present study quantified the effects of these BZ site agonists on cholinergic neurotransmission in the CeA region of the amygdala. The results are discussed in relation to two novel findings.
(1) When administered via microdialysis into the amygdala, eszopiclone and diazepam significantly increased ACh release in the amygdala, whereas midazolam and zolpidem did not significantly alter ACh release in the amygdala. (2) In contrast, IV administration of midazolam and eszopiclone caused a significant decrease in ACh release within the amygdala of isoflurane-anesthetized rats and of rats that were not anesthetized. The finding that ACh release in the amygdala was decreased by systemic delivery of midazolam and eszopiclone, but increased by amygdala delivery, indicates that these sedative/hypnotics decrease ACh release in the amygdala by altering the excitability of extra-amygdaloid neurons.
Acetylcholine and Amygdaloid Modulation of Sleep and Wakefulness
Cholinergic neurotransmission contributes to normal amygdaloid function. 2, [14] [15] [16] 25, 26 The amygdala is richly endowed with cholinergic terminals 27 many of which originate from neurons in the basal forebrain. 28 Amygdala neurons are depolarized by muscarinic receptor agonists, 29 and application of ACh to the amygdala increases neuronal discharge. 30 Normally, neuronal discharge in the amygdala is relatively quiescent, 31 and activation of the amygdala increases neurotransmitter release. 2, 32 Additional structure/function data emphasize the relevance of amygdala ACh levels for human amygdaloid function. For example, the human amygdala contains acetylcholinesterase, 33 and the neurotoxic acetylcholinesterase inhibitor soman increases firing rate in the amygdala to an extent that results in seizures. 34 Others have measured ACh in the amygdala during a learning task and found that increased ACh release was indicative of amygdala activation. 35 The effects of midazolam on sleep and electroencephalographic power are to increase a nonrapid eye movement sleep-like state, decrease rapid eye movement sleep, decrease electroencephalographic δ (0.5-4 Hz) power, and increase electroencephalographic σ (11-16 Hz) power. 36 Human brain imaging data show that the BZ site agonist triazolam, indicated for treatment of insomnia, causes deactivation of the amygdala. 37 Eszopiclone and zolpidem were included in the present study because they are also used for treatment of insomnia, a disorder in which the amygdala fails to deactivate during sleep. 1 No previous studies, however, have compared the effects of midazolam, diazepam, eszopiclone, and zolpidem on ACh release in the amygdala.
Midazolam and Eszopiclone Decrease ACh Release in the Amygdala
Midazolam consistently has been reported to produce an anxiolytic effect when administered into the basolateral amygdala. [38] [39] [40] [41] In addition, intraperitoneal administration of eszopiclone causes anxiolysis. 42 These findings fit with the concept that BZ site agonists produce their desired clinical actions by enhancing GABAergic inhibition, resulting in diminished neuronal excitability within the amygdala. This interpretative view of a mechanism of action of BZ site agonists also is consistent with the present finding that systemically administering midazolam and eszopiclone caused a significant decrease in ACh release in the amygdala of unanesthetized ( Fig. 3 ) and anesthetized ( Fig. 4) rats.
How is one to interpret the finding (Fig. 5 ) that the effects of BZ site agonists on ACh release in the amygdala vary as a function of systemic versus amygdala drug delivery? Figure 5 results support and extend previous neurochemical studies comparing the effect of diazepam, eszopiclone, and zolpidem on ACh release in medial regions of the pontine reticular formation, 17 a brain region known to regulate states of sleep and anesthesia. 43, 44 Unlike the present findings in amygdala ( Fig. 5 ), microdialysis delivery of zolpidem and eszopiclone into the pontine reticular formation caused a concentration-dependent increase in ACh release in the pontine reticular formation. 17 Similar to the present results with systemic drug administration ( Figs. 3 and 4) , IV administration of eszopiclone decreased ACh release in the pontine reticular formation of anesthetized and unanesthetized rats. 17 Comparing results obtained from the amygdala (Figs. 3, 4 , and 5) with data from the pontine reticular formation 17 permits two conclusions. First, the contrasting effects on ACh release of local versus systemic drug delivery emphasize the need for the multiple experimental approaches illustrated by Figure 1 . Microdialysis drug delivery to specific brain regions is a powerful tool for identifying receptor subtypes modulating transmitter release 45 and for elucidating autoreceptor function. 23 It is clear, however, that the results from studies using only microdialysis drug delivery do not permit strong inferences regarding the brain sites through which systemically administered drugs alter neurotransmitter levels. A drug delivered by microdialysis to a specific brain region may cause the same change in neurotransmitter levels that are caused by systemic delivery of that drug. In such a case, the principle of parsimony supports the conclusion that the brain region dialyzed has been identified as one site of action for the systemically administered drug. 17, 46, 47 For example, comparing the effects on neurotransmitter release caused by local versus systemic delivery of opioids has successfully identified the substantia innominata of the basal forebrain as one region through which IV opioids decrease cortical ACh release. 46 In the present study, the increase in ACh release caused by microdialysis delivery of diazepam and eszopiclone to the amygdala (Fig. 5) is contrary to the fact that ACh promotes behavioral and electrographic arousal, and contrary to the sedating actions of diazepam and eszopiclone. Thus, the present results ( Figs. 3, 4 , and 5) support an alternative conclusion that midazolam and eszopiclone decrease ACh release in the amygdala by acting on neuronal systems outside the amygdala.
Limitations and Future Directions
Microdialysis probes were aimed for the CeA region, but some dialysis sites were located in other amygdaloid nuclei due to the limited spatial resolution of microdialysis probes (Fig. 2) . Therefore, it is not possible to attribute the present ACh measures to any specific subregion of the amygdala. Many studies already have shown that administering sedative/hypnotics into the amygdala causes sedation and anxiolysis. [38] [39] [40] [41] In addition, sleep is increased by microinjecting cholinomimetics into the amygdala. 16, 48 To fill existing gaps in knowledge, and to satisfy the mandate for nonduplicative research, the present study focused on amygdala neurochemistry. The emphasis on changes in amygdala ACh release caused by BZ site agonists was stimulated by the recent discovery that the relationship between GABAergic and cholinergic neurotransmission modulates levels of behavioral arousal. 49 The present focus on ACh should not be interpreted, however, to imply primacy of cholinergic function in the amygdala. Multiple endogenous neurotransmitter systems (e.g., GABAergic, glutamatergic, noradrenergic, and histaminergic) are involved in regulating neuronal excitability within the amygdala. Unlike our previous studies characterizing ACh release as a function of drug concentration, 17, 45 the present experiments were limited to one concentration for each of the four BZ site agonists. The present study identifying concentrations of each drug that altered ACh release is an essential first step needed to justify future concentration-response studies.
We are aware of no data concerning the relative affinity or efficacy of midazolam for different α subtypes in any brain region. Understanding the GABA A receptor subtypes through which BZ site agonists alter the physiological and behavioral traits characteristic of sedation and sleep has the potential to help develop future BZ site agonists with highly specific actions. For example, studies using transgenic mice already have succeeded in demonstrating that the phenotypes of sedation and electroencephalographic power altered by diazepam are mediated by different α subtypes of the GABA A receptor. 50 Activation of GABA A receptors containing the α-1 subunit mediate sedation, whereas α-2 containing GABA A receptors mediate anxiolysis. 51 In conclusion, ACh release in the amygdala was decreased by systemic administration of midazolam and eszopiclone, and increased by direct administration of these drugs into the amygdala. This differential response indicates that these sedative/hypnotics change ACh release in the amygdala by altering the excitability of extra-amygdaloid neurons. The present results encourage future efforts to characterize the neuronal networks through which BZ site agonists alter the regulation of behavioral arousal by the amygdala. Cholinergic transmission in the pontine reticular formation plays a key role in regulating states of anesthesia and sleep. 43, 44 BZ site agonists alter ACh release in the pontine reticular formation, 17 and neurons in the amygdala provide excitatory input to the pontine reticular formation. 52 Continuing to derive a detailed understanding of the brain regions and neurotransmitters through which BZ site agonists cause sedation and sleep will advance what has been described as a new horizon for anesthesiology. 53 
